High	high	O	O
fat	fat	O	O
diet-fed	diet-fed	O	O
obese	obese	O	O
rats	rats	O	O
are	are	O	O
highly	highly	O	O
sensitive	sensitive	O	O
to	to	O	O
doxorubicin-induced	doxorubicin-induced	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
.	.	O	O

Often	often	O	O
,	,	O	O
chemotherapy	chemotherapy	O	O
by	by	O	O
doxorubicin	doxorubicin	O	O
(	(	O	O
Adriamycin	adriamycin	O	O
)	)	O	O
is	is	O	O
limited	limited	O	O
due	due	O	O
to	to	O	O
life	life	O	O
threatening	threatening	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
in	in	O	O
patients	patients	O	O
during	during	O	O
and	and	O	O
posttherapy	posttherapy	O	O
.	.	O	O

Recently	recently	O	O
,	,	O	O
we	we	O	O
have	have	O	O
shown	shown	O	O
that	that	O	O
moderate	moderate	O	O
diet	diet	O	O
restriction	restriction	O	O
remarkably	remarkably	O	O
protects	protects	O	O
against	against	O	O
doxorubicin-induced	doxorubicin-induced	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
.	.	O	O

This	this	O	O
cardioprotection	cardioprotection	O	O
is	is	O	O
accompanied	accompanied	O	O
by	by	O	O
decreased	decreased	O	O
cardiac	cardiac	O	O
oxidative	oxidative	O	O
stress	stress	O	O
and	and	O	O
triglycerides	triglycerides	S_chemicals	O
and	and	O	O
increased	increased	O	O
cardiac	cardiac	O	O
fatty-acid	fatty-acid	O	O
oxidation	oxidation	O	O
,	,	O	O
ATP	atp	S_chemicals	O
synthesis	synthesis	O	O
,	,	O	O
and	and	O	O
upregulated	upregulated	O	O
JAK/STAT3	jak/stat3	O	O
pathway	pathway	O	O
.	.	O	O

In	in	O	O
the	the	O	O
current	current	O	O
study	study	O	O
,	,	O	O
we	we	O	O
investigated	investigated	O	O
whether	whether	O	O
a	a	O	O
physiological	physiological	O	O
intervention	intervention	O	O
by	by	O	O
feeding	feeding	O	O
40	40	O	O
%	%	O	O
high	high	O	O
fat	fat	O	O
diet	diet	O	O
(	(	O	O
HFD	hfd	O	O
)	)	O	O
,	,	O	O
which	which	O	O
induces	induces	O	O
obesity	obesity	O	O
in	in	O	O
male	male	O	O
Sprague-Dawley	sprague-dawley	O	O
rats	rats	O	O
(	(	O	O
250	250	O	O
-	-	O	O
275	275	O	O
g	g	O	O
)	)	O	O
,	,	O	O
sensitizes	sensitizes	O	O
to	to	O	O
doxorubicin-induced	doxorubicin-induced	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
.	.	O	O

A	a	O	O
LD(10	ld(10	O	O
)	)	O	O
dose	dose	O	O
(	(	O	O
8	8	O	O
mg	mg	O	O
doxorubicin/kg	doxorubicin/kg	O	O
,	,	O	O
ip	ip	O	O
)	)	O	O
administered	administered	O	O
on	on	O	O
day	day	O	O
43	43	O	O
of	of	O	O
the	the	O	O
HFD	hfd	O	O
feeding	feeding	O	O
regimen	regimen	O	O
led	led	O	O
to	to	O	O
higher	higher	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
,	,	O	O
cardiac	cardiac	O	O
dysfunction	dysfunction	O	O
,	,	O	O
lipid	lipid	S_chemicals	O
peroxidation	peroxidation	O	O
,	,	O	O
and	and	O	O
80	80	O	O
%	%	O	O
mortality	mortality	O	O
in	in	O	O
the	the	O	O
obese	obese	O	O
(	(	O	O
OB	ob	O	O
)	)	O	O
rats	rats	O	O
in	in	O	O
the	the	O	O
absence	absence	O	O
of	of	O	O
any	any	O	O
significant	significant	O	O
renal	renal	O	O
or	or	O	O
hepatic	hepatic	O	O
toxicity	toxicity	O	O
.	.	O	O

Doxorubicin	doxorubicin	O	O
toxicokinetics	toxicokinetics	O	O
studies	studies	O	O
revealed	revealed	O	O
no	no	O	O
change	change	O	O
in	in	O	O
accumulation	accumulation	O	O
of	of	O	O
doxorubicin	doxorubicin	O	O
and	and	O	O
doxorubicinol	doxorubicinol	O	O
(	(	O	O
toxic	toxic	O	O
metabolite	metabolite	O	O
)	)	O	O
in	in	O	O
the	the	O	O
normal	normal	O	O
diet-fed	diet-fed	O	O
(	(	O	O
ND	nd	O	O
)	)	O	O
and	and	O	O
OB	ob	O	O
hearts	hearts	O	O
.	.	O	O

Mechanistic	mechanistic	O	O
studies	studies	O	O
revealed	revealed	O	O
that	that	O	O
OB	ob	O	O
rats	rats	O	O
are	are	O	O
sensitized	sensitized	O	O
due	due	O	O
to	to	O	O
:	:	O	O
(	(	B_chemicals	O
1	1	I_chemicals	O
)	)	O	O
higher	higher	O	O
oxyradical	oxyradical	O	O
stress	stress	O	O
leading	leading	O	O
to	to	O	O
upregulation	upregulation	O	O
of	of	O	O
uncoupling	uncoupling	B_chemicals	O
proteins	proteins	S_chemicals	O
2	2	O	O
and	and	O	O
3	3	O	O
,	,	O	O
(	(	B_chemicals	O
2	2	I_chemicals	O
)	)	O	O
downregulation	downregulation	O	O
of	of	O	O
cardiac	cardiac	O	O
peroxisome	peroxisome	B_chemicals	O
proliferators	proliferators	S_chemicals	O
activated	activated	O	O
receptor-alpha	receptor-alpha	O	O
,	,	O	O
(	(	B_chemicals	O
3	3	I_chemicals	O
)	)	O	O
decreased	decreased	O	O
plasma	plasma	O	O
adiponectin	adiponectin	S_chemicals	O
levels	levels	O	O
,	,	O	O
(	(	O	O
4	4	O	O
)	)	O	O
decreased	decreased	O	O
cardiac	cardiac	O	O
fatty-acid	fatty-acid	O	O
oxidation	oxidation	O	O
(	(	O	O
666.9+/-14.0	666.9+/-14.0	O	O
nmol/min/g	nmol/min/g	O	O
heart	heart	O	O
in	in	O	O
ND	nd	O	O
versus	versus	O	O
400.2+/-11.8	400.2+/-11.8	O	O
nmol/min/g	nmol/min/g	O	O
heart	heart	O	O
in	in	O	O
OB	ob	O	O
)	)	O	O
,	,	O	O
(	(	O	O
5	5	O	O
)	)	O	O
decreased	decreased	O	O
mitochondrial	mitochondrial	S_chemicals	S_disease
AMP-alpha2	amp-alpha2	O	O
protein	protein	B_chemicals	O
kinase	kinase	S_chemicals	O
,	,	O	O
and	and	O	O
(	(	O	O
6	6	O	O
)	)	O	O
86	86	O	O
%	%	O	O
drop	drop	O	O
in	in	O	O
cardiac	cardiac	O	O
ATP	atp	S_chemicals	O
levels	levels	O	O
accompanied	accompanied	O	O
by	by	O	O
decreased	decreased	O	O
ATP/ADP	atp/adp	O	O
ratio	ratio	O	O
after	after	O	O
doxorubicin	doxorubicin	O	O
administration	administration	O	O
.	.	O	O

Decreased	decreased	O	O
cardiac	cardiac	O	O
erythropoietin	erythropoietin	O	O
and	and	O	O
increased	increased	O	O
SOCS3	socs3	S_chemicals	O
further	further	O	O
downregulated	downregulated	O	O
the	the	O	O
cardioprotective	cardioprotective	S_chemicals	O
JAK/STAT3	jak/stat3	O	O
pathway	pathway	O	O
.	.	O	O

In	in	O	O
conclusion	conclusion	O	O
,	,	O	O
HFD-induced	hfd-induced	O	O
obese	obese	O	O
rats	rats	O	O
are	are	O	O
highly	highly	O	O
sensitized	sensitized	O	O
to	to	O	O
doxorubicin-induced	doxorubicin-induced	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
by	by	O	O
substantially	substantially	O	O
downregulating	downregulating	O	O
cardiac	cardiac	O	O
mitochondrial	mitochondrial	S_chemicals	S_disease
ATP	atp	S_chemicals	O
generation	generation	O	O
,	,	O	O
increasing	increasing	O	O
oxidative	oxidative	O	O
stress	stress	O	O
and	and	O	O
downregulating	downregulating	O	O
the	the	O	O
JAK/STAT3	jak/stat3	O	O
pathway	pathway	O	O
.	.	O	O

